Rangwala Reshma 4
4 · Karyopharm Therapeutics Inc. · Filed Apr 22, 2026
Research Summary
AI-generated summary of this filing
Karyopharm (KPTI) EVP/CMO Reshma Rangwala Sells 449 Shares
What Happened Reshma Rangwala, EVP and Chief Medical Officer of Karyopharm Therapeutics (KPTI), sold 449 shares on April 21, 2026. The shares were disposed at $8.94 per share for a total proceeds of approximately $4,014. The filing shows this was a broker-assisted sale to satisfy tax withholding on vested restricted stock units (RSUs), not a discretionary trade by the reporting person.
Key Details
- Transaction date: 2026-04-21; Filing date: 2026-04-22 (timely).
- Transaction type/code: Sale (S) — open market / broker-assisted sale.
- Shares sold: 449 at $8.94 per share; total proceeds ≈ $4,014.
- Footnote: Sale effected under a durable automatic sale instruction plan (adopted April 4, 2022) to cover withholding tax on RSU vesting; not a discretionary trade.
- Shares owned after the transaction: Not specified in the information provided.
Context This was a tax-withholding sale tied to RSU vesting rather than a voluntary market-timed sale. Such broker-assisted or withholding sales are common and primarily administrative; they do not necessarily reflect the insider’s view on the company’s prospects.
Insider Transaction Report
- Sale
Common Stock
[F1]2026-04-21$8.94/sh−449$4,014→ 56,290 total
Footnotes (1)
- [F1]This transaction was effected pursuant to a durable automatic sale instruction plan adopted by the reporting person on April 4, 2022, and represents a broker-assisted sale of shares to satisfy the payment of withholding tax liability incurred upon the vesting of restricted stock units. The sale does not represent a discretionary trade by the reporting person.